Oncolytic Virus in Gliomas: A Review of Human Clinical Investigations
Gliomas remain one of the more frustrating targets for oncologic therapy. Glioma resistance to conventional therapeutics is a product of their immune-privileged milieu behind the blood-brain barrier, in addition to their suppressive effect on the immune response itself. Taking the lead from the growing success of immunotherapy for systemic cancers, such as lung cancer and melanoma, immunotherapeutics has emerged as a major player in the potential treatment of gliomas, with oncolytic viruses in particular showing significant promise as evidenced by the recent Breakthrough and Fast Tract Designations for PVSRIPO and DNX2401. This review serves as a useful and updated compendium of the completed human clinical investigations for several oncolytic viruses in the treatment of gliomas.
Carpenter, A. B., Carpenter, A. M., Aiken, R., & Hanft, S. (2021). Oncolytic Virus in Gliomas: A Review of Human Clinical Investigations. Annals of Oncology, 32 (8), 968-982. https://doi.org/10.1016/j.annonc.2021.03.197